Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • Publications
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • Publications
  • In the News

Navidea Biopharmaceuticals to Present at the Virtual Investor Fireside Chat Series

Jun 9, 2020

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress

Jun 3, 2020

Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis

May 21, 2020

Navidea Biopharmaceuticals Reports First Quarter 2020 Financial Results

May 14, 2020

Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK®

May 11, 2020

Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update

May 7, 2020

Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic

Apr 22, 2020

Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea’s Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates

Mar 31, 2020

Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®

Mar 20, 2020

Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

Mar 11, 2020
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...43
    © 2023 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    linkedin
    Privacy Policy Disclaimer Sitemap